Efficacy of Sacubitril/Valsartan for the Treatment of Heart Failure with Moderately Reduced and Preserved Ejection Fraction
Keywords:
sacubitril/valsartan, heart failure, art failure with mildly reduced ejection fraction, heart failure with preserved ejection fraction, worsening heart failureAbstract
Heart failure with mildly reduced ejection fraction and heart failure with preserved ejection fraction are associated with significant morbidity and mortality, as well as growing economic burden. This review describes recent studies on the use of sacubitril/valsartan in heart failure patients with mildly reduced or preserved ejection fraction.
References
Жиров И.В., Сафронова Н.В., Терещенко С.Н. Сакубитрил/валсартан у пациентов с умеренно сниженной или сохраненной фракцией выброса и ухудшением сердечной недостаточности. Терапевтический архив. 2023;95(9):802–809. DOI: 10.26442/00403660.2023.09.202400 © ООО «КОНСИЛИУМ МЕДИКУМ», 2023 г.
Savarese G, Becher PM, Lund LH, et al. Global burden of heart failure:a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023;118(17):3272-87. DOI:10.1093/cvr/cvac013
Хроническая сердечная недостаточность, клинические рекомендации Минздрава России, 2020 г. Режим доступа: https://cr.minzdrav. gov.ru/recomend/156_1. Ссылка активна на 07.09.2023 [Chronic heart failure, clinical recommendations of the Russian Ministry of Health, 2020. Available at: https://cr.minzdrav.gov.ru/recomend/156_1. Accessed: 07.09.2023 (in Russian)].
McDonagh TA, Metra M, Adamo M, et al. ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-726. DOI:10.1093/eurheartj/ehab368
Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/ HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-1032. DOI:10.1161/CIR.0000000000001063
Talha KM, Butler J. Breakthroughs in the treatment of heart failure with mildly reduced and preserved ejection fraction. Clin Cardiol. 2022;45 Suppl. 1(Suppl. 1):S31-39. DOI:10.1002/clc.23846
Norova Gulnoz Sharifovna. (2023). FEATURES OF THE QUALITY OF LIFE OF PATIENTS WITH RESPIRATORY DISEASES AND THEIR DYNAMICS DURING STATIONARY TREATMENT. International Journal of Integrative and Modern Medicine, 1(1), 66–73. Retrieved from http://medicaljournals.eu/index.php/IJIMM/article/view/25
